Moderna, Inc. (SWX:MRNA)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 78.14B +846.8% |
| Revenue (ttm) | 2.11B +13.1% |
| Net Income | -2.33B |
| EPS | -5.88 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 206.90 |
| Day's Range | n/a |
| 52-Week Range | 19.65 - 226.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine.
Moderna Transcript: Analyst Day 2026
2026 vaccine growth guidance rose to 15%-25%, while gross margin reached a projected 65%. Intismeran’s positive phase III melanoma results underpin a potential 2027 launch and increased investment, supported by a purpose-built manufacturing and commercial infrastructure.
Moderna Press release: FY 2026
Moderna issued a press release on November 12, 2026, disclosing material business information to investors.
Moderna Slides: FY 2026
Moderna has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 12, 2026.
The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Moderna highlights FY27 commerical growth opportunities
The company said, “Moderna’s (MRNA) strategy is built on an integrated mRNA platform combining mRNA science, delivery technologies and manufacturing capabilities. By developing modalities that share u...
Moderna says Marlborough expected to become global supply site for intismeran
The company said, “Manufacturing is a core component of Moderna’s (MRNA) integrated mRNA platform, supporting commercial vaccine supply, strategic partnerships and the potential launch of individualiz...
Moderna outlines next phase of growth at Analyst Day
Moderna (MRNA) outlined the next phase of growth at its 2026 Analyst Day, highlighting how more than a decade of investment in the Company’s mRNA platform has enabled the development…
Moderna now sees 2026 revenue growth 15%-20%
Moderna (MRNA) expects 2026 revenue growth of 15% to 25%, compared with the original outlook of up to 10%, and is on track to achieve approximately 10 percentage points of…
Moderna announces publication of real-world mNEXSPIKE effectiveness data in JAMA
Moderna (MRNA) announced the publication of results from a large real-world study evaluating the comparative effectiveness of mNEXSPIKE and Comirnaty among U.S. Veterans aged 65 years and older during...
Moderna price target raised to $305 from $230 at Piper Sandler
Piper Sandler raised the firm’s price target on Moderna (MRNA) to $305 from $230 and keeps an Overweight rating on the shares following the company’s earnings report. The firm anticipates…
Moderna price target raised to $195 from $137 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna (MRNA) to $195 from $137 and keeps a Neutral rating on the shares. Moderna delivered a significant Q3…
Moderna price target raised to $260 from $220 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $260 from $220 and keeps a Neutral rating on the shares after what the firm calls a “clean beat and…
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
British drugmaker GSK has settled lawsuits that accused Moderna's [COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.
Moderna price target raised to $145 from $130 at RBC Capital
RBC Capital raised the firm’s price target on Moderna (MRNA) to $145 from $130 and keeps a Sector Perform rating on the shares.
Moderna price target raised to $110 from $90 at TD Cowen
TD Cowen analyst Tyler Van Buren raised the firm’s price target on Moderna (MRNA) to $110 from $90 and keeps a Hold rating on the shares. “Strong” and balanced U.S.
Moderna Stock (MRNA) Gains After COVID-Fueled Q3 Earnings Beat
Shares in drugs group Moderna ($MRNA) rose in pre-market trading as its Q3 earnings continued to be buoyed by COVID and it upped its full-year revenue forecasts. It said that…
Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.
Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.
Moderna Earnings Call Transcript: Q3 2026
Q3 revenue rose 29% YoY to $1.3B and net income was $162M; FY2026 revenue growth guidance was raised, with lower cash-cost and capex targets. Intismeran delivered positive Phase III melanoma results as respiratory approvals expanded.
Moderna Earnings release: Q3 2026
Moderna released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
Moderna Slides: Q3 2026
Moderna has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 6, 2026.
Moderna Quarterly report: Q3 2026
Moderna has published its Q3 2026 quarterly earnings report on November 6, 2026.
Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit
The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.
Moderna sees year-end 2026 cash and investments $8.1B-$8.3B
The company now expects year-end 2026 cash and investments of approximately $8.1 billion to $8.3 billion, increased from its previous outlook of $4.7 billion to $5.2 billion. The increase reflects…
Moderna up 10% to $267.36 after raising FY26 revenue growth view
07:16 EST Moderna (MRNA) up 10% to $267.36 after raising FY26 revenue growth view